Onconova Announces Upcoming Presentations Related to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Onconova Announces Upcoming Presentations Related to Advanced Rigosertib Clinical Trials at 2016 ASCO Annual Meeting

NEWTOWN, Pa., May 31, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX ), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced details relating to two poster presentations at the upcoming 2016 American Society of Clinical Oncology Annual Meeting taking place June 3-7 in Chicago, Illinois.

Rationale and Mechanism of Action for Rigosertib/Azacitidine Combination Therapy

Poster Presentation with Discussion* Abstract Number: 7020  Title: Rigosertib (RIG) in combination with azacitidine (AZA) to modulate epigenetic effects and to overcome clinical resistance to hypomethylating agents (HMA) in myelodysplastic syndromes (MDS). Session Name: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Date: Monday, June 6, 2016                                                                                                                      Time and Location: 8:00 AM – 11:30 AM, McCormick Place, Hall A                                                        Presenter: Pratima Chaurasia, PhD, Icahn School of Medicine at Mount Sinai

*Poster discussion session on Monday, June 6, 2016 from 11:30 AM – 12:45 PM

Design of Phase 3 INSPIRE Trial for Second -line Higher-risk Myelodysplastic Syndromes

Poster Presentation Abstract Number: TPS7077  Title: INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs)—Study design informed by subgroup analyses of ONTIME.                                                                                        Session Name: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Date: Monday, June 6, 2016                                                                                                                      Time and Location: 8:00 AM – 11:30 AM, McCormick Place, Hall A                                                    Presenter: Guillermo Garcia-Manero, MD, MD Anderson Cancer Center, Houston, TX

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are clinical stage, and several candidates are in pre-clinical stages.  For more information, please visit  http://www.onconova.com .

About Rigosertib

Rigosertib is a small molecule inhibitor of cellular signaling and acts as a RAS mimetic. These effects of rigosertib appear to be mediated by direct binding of the compound to the RAS-binding domain (RBD) found in many RAS effector proteins, including the Raf kinases and PI3K. The therapeutic focus for rigosertib is myelodysplastic syndromes (MDS), a group of bone marrow disorders characterized by ineffective formation of blood cells that often converts into acute myeloid leukemia (AML). Clinical trials for rigosertib are being conducted at leading institutions in the United States, Europe, and the Asia-Pacific region. Rigosertib is protected by issued patents (earliest expiry in 2026) and has been awarded Orphan Designation for MDS in the United States, Europe and Japan.

About INSPIRE

The IN ternational S tudy of P hase III I V R igos E rtib, or INSPIRE, is based on guidance received from the  U.S. Food and Drug Administration and European Medicines Agency and derives from the findings of the ONTIME Phase 3 trial.  INSPIRE is a multi-center, randomized controlled study to assess the efficacy and safety of IV rigosertib in HR-MDS patients who had progressed on, failed to respond to, or relapsed after previous treatment with an HMA within the first nine months of initiation of HMA treatment.  This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines.  The trial will enroll approximately 225 patients randomized at a 2:1 ratio into two treatment arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.  The primary endpoint of INSPIRE is overall survival and an interim analysis is anticipated. Full details of the INSPIRE trial, such as inclusion and exclusion criteria, as well as secondary endpoints, can be found on clinicaltrials.gov (NCT02562443). 

Forward Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events or Onconova Therapeutics, Inc.'s future operations, clinical development of Onconova's product candidates and presentation of data with respect thereto, regulatory approvals, expectations regarding the sufficiency of Onconova's cash and other resources to fund operating expenses and capital expenditures, Onconova's anticipated milestones and future expectations and plans and prospects. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including Onconova’s need for additional financing and current plans and future needs to scale back operations if adequate financing is not obtained, the success and timing of Onconova’s clinical trials and regulatory approval of protocols, and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q.

Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

 

CONTACT: Onconova Therapeutics Benjamin Hoffman, 267-759-3036 bhoffman@onconova.us

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 151

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 109

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 43

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 16

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 21

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 17

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 34

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 24

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 49

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 362

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating a Milestone: Gifting the 400th Home to a Veteran

Updated Category News Views 339

Celebrating a Milestone with 400th Home Gift Building Homes for Heroes and Hillwood Properties proudly partnered to celebrate a significant milestone by gifting a home to U.S. Army Specialist Joshua Sager and his family. This remarkable achievement signifies the organization’s commitment to providing veterans and first responders with the means to establish a fresh...

Continue Reading
Wheeler REIT Achieves Record Price as Growth Continues

Updated Category News Views 259

Wheeler REIT Reaches New Milestone In an extraordinary demonstration of resilience and upward momentum, Wheeler Real Estate Investment Trust (WHLRD) has achieved a remarkable milestone by hitting a 52-week high of $27.49 USD. This achievement reflects the company's strong performance and investor confidence in its strategic direction. Strong Financial Position Recent data...

Continue Reading
S&P Global Splits Off Mobility Unit: Investor View

Updated Category News Views 52

Strategic Moves Shake Up S&P Global Listen up, traders! You don’t want to miss what S&P Global, ticker NYSE:SPGI, is cooking up. They've given the green light to split off their Mobility division, officially birthing Mobility Global Inc. This shake-up promises to stir some excitement in the market. Buckle up, because here's what this movement means for you and your...

Continue Reading
Carvana's Q3 Earnings Surge Promises Bright Future for CVNA

Updated Category News Views 103

Carvana Shares Soar After Impressive Q3 Earnings Report Recently, Carvana (NYSE: CVNA), a leading online used-car retailer, experienced a significant surge in its stock price as a result of a positive earnings announcement for the third quarter. The encouraging outlook provided by the company has delighted investors, pushing shares upward during premarket trading....

Continue Reading
PHINIA Unveils Comprehensive Guide to International Emission Standards

Updated Category News Views 150

PHINIA Unveils New Emission Standards Guide for 2024/25 PHINIA Inc. (NYSE: PHIN), a leading name in premium fuel systems and electrical solutions, has launched its latest 2024/25 Emission Standards Booklet specifically designed for heavy-duty and off-road vehicles, engines, and machinery. This guide is unique as it serves as the only complete resource available to keep...

Continue Reading